# Niagen Bioscience share price today (Niagen Bioscience, Inc., NAGE)

> Niagen Bioscience, Inc.'s P/E is near the low end of its own history, higher than only 0% of past readings, and its quarterly results are still getting worse. NAGE · Healthcare · Biotechnology · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/nage

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $2.36 (−68.7% in a year)
- P/E: 12.4× (lower than 100% of the last 1 year)
- Revenue (Jun 2026): $29.8 M (−4.3% on a year ago)
- Profit (Jun 2026): $963 K (−73.3% on a year ago)
- Operating margin: 2.4% (−7.8 points on a year ago)
- ROE: 23%, FY25
- ROIC: 44.0%, against a 15.5% cost of capital: +28.5 points
- Profit that came in as cash: 99%, last 2 years

The main question: yearly earnings per share moved +81.8% while the share price moved −68.7%. ## What is the Niagen Bioscience share price today? Niagen Bioscience, Inc.'s share price was $2.36 at the close on 3 November 2026. That is 39.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $7, and at that close it sat 1% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 57 weeks running. Over the last 1 year the share price moved −79% while the S&P 500 moved +21%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Niagen Bioscience pay? Niagen Bioscience, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Niagen Bioscience on? Niagen Bioscience is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Niagen Bioscience profitable? Niagen Bioscience, Inc. earned $963 K of net profit in the Jun 2026 quarter, −73.3% on the same quarter a year earlier. Full-year FY25 profit was $17.4 M. That is 3.2% of the quarter's revenue. The same quarter a year earlier earned $3.6 M. 3 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $17.4 M (+103.3% on the year before). Why profit moved: revenue changed −4.3% on a year earlier and the margin moved −7.8 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +13.2% and revenue +12.0%. Profit and revenue are moving at about the same pace. ## How much revenue does Niagen Bioscience make, and is it growing? Niagen Bioscience, Inc. reported $29.8 M of revenue in the Jun 2026 quarter, −4.3% on the same quarter a year earlier. Over 4 years it has grown 17.7% a year on average. The last full year, FY25, came in at $129 M. The last four reported quarters add to $129 M. FY25 revenue was $129 M, +29.9% on the year before. Recent pace: the last four quarters grew +12.0% on average, against 17.7% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +11.0%, against +22.8% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Niagen Bioscience keep? Niagen Bioscience, Inc.'s operating margin was 2.4% in the Jun 2026 quarter, 7.8 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −40.1% and 11.0%. The latest quarter is within that range. Across 5 years it has been between −40.1% and 11.0%, and FY25's 11.0% is the highest of them. Why the margin moved: operating margin changed −7.8 percentage points on the year while gross margin changed −0.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Niagen Bioscience's profit turning into cash? Over the last 2 years, 99% of Niagen Bioscience, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $13.5 M of operating cash against $17.4 M of profit. After $292 K of spending on assets, $13.2 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Niagen Bioscience's cash go? Niagen Bioscience, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $603 K on assets over the last 3 years. Averaged over those years that is 0.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $603 K over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Niagen Bioscience's P/E ratio, and how does it compare with its own history? Niagen Bioscience, Inc.'s P/E is 12.4×, about the lowest it has ever been. Its usual P/E (the middle reading) is 24.1×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +81.8% while the price moved −68.7%. Earnings did better than the price, which pulled the multiple down within its own range. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Niagen Bioscience business getting better or worse? Niagen Bioscience, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Niagen Bioscience earn on its capital? Niagen Bioscience, Inc. earned a ROE of 23% in FY25. That is up from a low of −86% in FY21. Its return on capital used (ROIC) is 28.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 13.4% net margin and 1.22× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 13.4% net margin × 1.22× asset turnover × 1.39× leverage (assets divided by equity) ≈ 22.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 44.0% − 15.5% = +28.5 percentage points. The 15.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 44.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 144.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Niagen Bioscience have too much debt? Niagen Bioscience, Inc. has total debt of $2.3 M against shareholder equity of $82.5 M as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.15 in FY21 to 0.04 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Niagen Bioscience shareholding pattern? 7.1% of Niagen Bioscience, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 7.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Niagen Bioscience from balance-sheet trouble? For Niagen Bioscience, Inc., the Z-score is 13.60. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 13.60 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Niagen Bioscience rank in its industry? There is no score against its industry: Niagen Bioscience, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Niagen Bioscience compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Niagen Bioscience in size? Niagen Bioscience is the 197th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Cartesian Therapeutics, Inc., ProQR Therapeutics N.V. and Compugen. Just below it: Upstream Bio, Inc., Whitehawk Therapeutics, Inc. and Invivyd, Inc. ### Biotechnology companies close in size

1. [Cartesian Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/rnac) $194 million
2. [ProQR Therapeutics N.V.](https://www.sectoralpha.in/us/stocks/prqr) $193 million
3. [Compugen Ltd.](https://www.sectoralpha.in/us/stocks/cgen) $190 million
4. Niagen Bioscience, Inc. $187 million
5. [Upstream Bio, Inc.](https://www.sectoralpha.in/us/stocks/upb) $186 million
6. [Whitehawk Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/whwk) $177 million
7. [Invivyd, Inc.](https://www.sectoralpha.in/us/stocks/ivvd) $171 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

## What else do people ask about Niagen Bioscience? ### What were Niagen Bioscience's latest quarterly results? Niagen Bioscience, Inc. reported revenue of $29.8 M and net profit of $963 K for the Jun 2026 quarter. Revenue fell 4.3% and profit fell 73.3% compared with a year earlier. Earnings per share were $0.01. The operating margin was 2.4%, 7.8 percentage points lower than a year earlier (as of 3 November 2026). ### What is Niagen Bioscience's market cap? Niagen Bioscience, Inc.'s market capitalisation is $187 M at a stock price of $2.36. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Niagen Bioscience performing? Niagen Bioscience, Inc.'s latest readings are below. In its latest quarter, revenue fell 4.3% and profit fell 73.3% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 57 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Niagen Bioscience's stock price go up? This page does not forecast Niagen Bioscience, Inc.'s stock price. What it shows instead: the stock price is $2.36. Its P/E of 12.4× is higher than 0% of its own last 1 years. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Niagen Bioscience in its business cycle? Niagen Bioscience, Inc.'s FY25 operating margin was 11.0%, against a 5-year range of −40.1% to 11.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 2.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Niagen Bioscience story? The main question: yearly earnings per share moved +81.8% while the share price moved −68.7%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Niagen Bioscience a stock worth studying right now? What the numbers show: Niagen Bioscience, Inc.'s P/E is near the low end of its own history, higher than only 0% of past readings, and its quarterly results are still getting worse. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.